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Proteomic technologies hold great promise in the search for
clinically useful protein biomarkers for the early detection,
diagnosis and prognosis of cancer and for monitoring response
to therapy. Moreover, they have the potential for contributing to
the discovery of novel drug targets and for testing the biochemical
effects of drugs on cells and tissues and to define cancer-related
molecular events. This book, from the Cancer Drug Discovery and
Development Series, provides the reader with a current perspective
and anticipated uses of proteomic strategies in cancer therapy as
well as basic cancer research.
The book is divided into four parts, beginning with a detailed
background on current proteomic technologies. The chapter
describes mass spectrometry-based methods and strategies for
studying protein phosphorylation and the quantitation of proteins
for expression profiling. Although a technical subject, the authors
have not overcomplicated the topic, and the chapter provides
the non-specialist reader with an understandable background to the
methods and also details some of the technical challenges associated
with proteomic analysis. The second part of the book plunges the
reader into the topic of cell signalling proteomics, with two very
specific chapters on the integration of genomics and proteomics for
the study of p53 signalling, and the profiling of tyrosine kinases as
pharmacological end points for targeted cancer therapy. The general
methods and background to the signalling pathways and tyrosine
kinase inhibitors with therapeutic use are well described in both
chapters, and work in these areas is well-referenced. However,
chapter 2 includes an abundance of experimental data from the
authors’ own laboratory, drawing the reader away from the focus of
the book, and although chapter 3 promises an interesting section on
clinical phospho-proteomics, it fails to deliver.
The third part of the book describes clinical applications of
proteomics in cancer therapy, although few, if any, proteomic-
based tests are actually used in the clinic. This part of the book is
perhaps inaccurately entitled ‘Tumour Proteomics’, as it covers an
array of topics from oncoproteomics for personalised manage-
ment, through serum proteomics for cancer detection, to strategies
of therapeutic individualisation and target discovery in AML. In
chapter 4, the concept of the cancer biomarker is introduced along
with the role of proteomics in the discovery of biomarkers for
diagnosis, monitoring cancer progression, predicting recurrence,
assessing response/efficacy of treatment and selecting patients for
given therapies. Several more methodologies and strategies for
biomarker discovery are briefly described, although are inade-
quately referenced. The section is poorly organised and it is not
clear how clinically useful such approaches are or will be in the
future, particularly for directing personalised therapies. Chapter 5
reads much better, dealing with serum and tissue proteomics and
the incorporation of proteomic tests into clinical trials where they
are expected to provide useful end points. The introduction
describes currently used serum tumour markers, discusses their
inadequacies and emphasizes the need for better cancer
biomarkers. Several proteomics methods are again described
(gel electrophoresis, mass spectrometry, protein arrays, and so
on), which would have been better placed in the first section of
the book.
Chapters 6–8 provide specific examples of the use of proteomics
in the study of renal cell carcinoma, lung cancer and acute
leukaemia. Again there are informative backgrounds for the non-
specialist reader and several interesting sections on tumour
antigens, the importance of sample selection and preparation,
molecular diagnosis and classification of cancer using proteomics,
multiplexed immune-based protein assays and drug target valida-
tion using proteomics. Chapter 9 is excellent and deals with
practical aspects of tumour biomarker discovery; a must for all new
researchers to the field, although would have been better placed
earlier in the book. It describes guidelines for the development and
introduction of biomarkers to the clinic and has first-rate sections
on pre-analytical, analytical and post-analytical aspects of biomarker
assessment and the clinical uses of biomarkers in cancer.
The final part of the book covers bioinformatics and regulatory
aspects of proteomics. Chapter 10 provides a useful overview on
efforts to annotate the human proteome, references useful data
resources and, importantly, highlights the need and global initi-
atives for standardising the reporting and storage of proteomic
information from different sources. The final chapter deals with
regulatory issues in the co-development of drugs and proteomic
tests. It includes the role of the Food and Drug Administration
(FDA) in regulating the use of proteomics in cancer therapy and
covers issues of target characterisation, intended use and
indication for use, method and operation standardisation and
the importance of study design.
Despite the reservations outlined above, the book provides a
broad account of the area of cancer proteomics and adequately
covers issues relevant to the use of proteomic strategies in clinical
research. There are useful reviews of different methodologies, work
in different cancer types, on biomarker development and clinical
use and on bioinformatics and regulatory aspects of proteomics.
The book would be of interest to clinicians and basic cancer
researchers alike who are already involved in, or who are
considering the use of proteomics in their work. However, the
book also reveals that clinical proteomics is still in its infancy, that
biomarker research is firmly in the early discovery phase and that
there has been little clinical validation of the many recently
reported ‘biomarkers’ of cancer. Thus, although proteomics has
contributed significantly to our understanding of the molecular
biology of cancer, it is a sad fact it has yet to deliver any clinically
useful biomarkers.
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